Case Report

How a Devastating Case of *Acanthamoeba* Sclerokeratitis Ended up with Serious Systemic Sequelae

Sophie Bataillie Rita Van Ginderdeuren Joachim Van Calster
Beatrijs Foets Heleen Delbeke

Ophthalmology, University Hospital Leuven, Leuven, Belgium

Keywords

Acanthamoeba keratitis · *Acanthamoeba* sclerokeratitis · Nodular scleritis · Enucleation

Abstract

A 35-year old soft contact lens wearer with a proven bilateral *Acanthamoeba* keratitis developed a nodular scleritis. Based on the stepladder approach described by Iovieno et al. [Ophthalmology. 2014 Dec;121(12):2340–7], nonsteroidal anti-inflammatory drugs, methylprednisolone, and later azathioprine were added to the anti-amoebic treatment. Unfortunately, there was further deterioration and an endophthalmitis developed. Unbearable pain and concerns of spread to the brain urged an enucleation. Histopathological examination confirmed *Acanthamoeba* cysts in the cornea, sclera, retina, choroid, and vitreous body. As a side effect of the immunosuppressive treatment, the patient developed myopathy, pulmonary aspergillosis, and an avascular necrosis of the hip. Scleritis is a devastating complication of *Acanthamoeba* keratitis with a poor prognosis and a high enucleation rate. *Acanthamoeba* sclerokeratitis is, due to cyst-free biopsies, mostly assigned to an immune-mediated mechanism, justifying the use of immunosuppressive treatment. Scleritis in our case contributed to the extracorneal spread of *Acanthamoeba*. Our case is the first documented extracorneal spread of *Acanthamoeba* without previous surgery. Extracorneal spread of *Acanthamoeba* should be considered, even in the case of false-negative biopsies. We strongly recommend serial sections of the retrieved scleral specimen in case of negative histopathological examination to exclude an infection. Even when an immune-mediated scleritis is suspected, systemic immunosup-

pressive treatment should always be used with the greatest caution. Awareness of the side effects and monitoring by an experienced physician is mandatory.

© 2020 The Author(s)
Published by S. Karger AG, Basel

Introduction

Acanthamoeba is a protozoan, having a life cycle consisting of trophozoite and cyst stages. The trophozoite is the infectious form causing corneal ulcers, especially in contact lens wearers. These trophozoites change into a double-walled dormant cystic form whenever the environment is hostile. It is in particular this double wall that makes the treatment of this infection so difficult and prolonged. Research proved that a delay of >3 weeks between diagnosis and symptoms worsen the outcome [1, 2]. *Acanthamoeba* scleritis is a rare and painful complication of *Acanthamoeba* keratitis, affecting 10–18% of patients [3–5]. The pathogenesis of *Acanthamoeba* sclerokeratitis is still poorly understood, and it is unclear whether it is immune-mediated or real spread of the infection causes this painful evolution [6]. This uncertainty makes it very difficult to treat, resulting in poor outcome.

We report a patient with histopathologically proven *Acanthamoeba* sclerokeratitis and uncontrollable endophthalmitis. The immunosuppressive agents used to control his sclerokeratitis led to severe secondary complications.

Case Report

A healthy 35-year-old soft contact lens wearer presented with bilateral peripheral stromal infiltrates over 360° causing a foreign body sensation. At presentation, his vision was 0.3 (logMAR) in both eyes and he had already been on topical corticosteroids for 1 week. Corneal scrape with histopathological examination and an agar enriched with *Escherichia coli* were both positive for *Acanthamoeba*. Topical treatment with polyhexamethylene biguanide 0.02% and propamidine isethionate 0.1% once every hour, continued overnight for the first 24 h, moxifloxacin 0.5% six times a day, and atropine 1% twice a day was started. Under this treatment, the right eye improved rather quickly to a vision of 0.8 (logMAR), but the left eye deteriorated. After 15 days of intense anti-amoebic treatment, the patient presented with keratic precipitates and anterior chamber inflammation. Topical prednisolone 1% four times a day was added to the treatment. The topical corticosteroids improved the inflammation, but recurrence was noticed after tapering down. One month after the initial diagnosis, propamidine isethionate was replaced by chlorhexidine 0.02% due to lack of improvement. Furthermore, based on the knowledge that 10–23% of *Acanthamoeba* keratitis cases may be polymicrobial or coinfecting with herpes simplex virus, oral acyclovir was added [1]. After 3 months of intensive treatment, unbearable pain and marked conjunctival injection made us stop all drops for 2 days to exclude treatment-induced toxicity and to repeat the corneal scrape for histopathological examination, culture, and PCR. After stop of the treatment there was no improvement and the culture came back positive for yeast (unspecified). Amphotericin B drops 0.15% six times a day and oral itraconazole 100 mg was added to the anti-amoebic treatment of chlorhexidine 0.02%, Desomedine 0.1%, and polyhexamethylene biguanide 0.02%, all six times a day, and the oral antiviral treatment.

Five months after the initial presentation, the patient was in severe pain, and an anterior scleritis with a painful nodule was diagnosed on ultrasound (Fig. 1). An immune-mediated scleritis due to *Acanthamoeba* keratitis was suspected (Fig. 2). Based on the step-ladder

approach described by Iovieno et al. [5], oral ibuprofen 600 mg three times a day, topical nepafenac 0.1% once a day and, in a later stage, intravenous solumedrol 1 g for 3 days followed by methylprednisolone orally could not improve his scleritis. Azathioprine 150 mg a day was added to the treatment. A few days later, a new epithelial defect and corneal edema developed. Repeat histopathological examination reported *Acanthamoeba* cysts. A serious anterior and posterior chamber inflammation emerged under high-dose topical anti-amoebic treatment in combination with the azathioprine and methylprednisolone. Because of the uncontrollable intraocular inflammation and a doubtful result on an earlier vitreous biopsy, a three-port hybrid 27- to 23-gauge vitrectomy combined with lensectomy and Siluron® 2000 oil filling of the eye was performed. Retinal necrosis and edema of the optic disc became visible during surgery. An MRI of the brain did not show intracranial spread of the infection, but the unbearable pain in combination with the fear of spread to the brain made us perform an enucleation of the left eye.

Our immunocompetent patient, who was a passionate long-distance runner at diagnosis, developed a series of adverse events due to the immunosuppressive therapy that he took for 3 months. Besides anemia and elevated lactate dehydrogenase, thoracic imaging showed multiple lung nodules 4 months after start of the immunosuppressive treatment. Biopsy of these nodules showed hyphae, compatible with *Aspergillus* pneumonia, most probably related to the immunosuppressive treatment. In addition to this, he experienced severe myopathy with muscle weakness and atrophy of the proximal muscles in the lower limbs due to the oral steroids used. Two years after the enucleation, the patient presented with pain in his right hip and the diagnosis of avascular necrosis of the hip, a known complication of high-dose steroids, was made [7].

Histopathological examination of the enucleated eye showed a cornea with *Acanthamoeba* cysts in the stroma and decreased endothelial cells. The sclera was infiltrated by lymphocytes and histiocytes in combination with *Acanthamoeba* cysts in the superficial and deeper layers. Intraocularly, the vitreous body, the retina, the choroid, and even the subretinal and subchoroidal layers were infiltrated by lymphocytes, macrophages, and histiocytes. In the retina, an excessive amount of *Acanthamoeba* cysts were present. The optic nerve was atrophic, but without inflammation and *Acanthamoeba* cysts (Fig. 3).

Discussion

The increasing incidence of *Acanthamoeba* keratitis over the last 10 years makes it even more important to create awareness as regards potential serious sequelae [8]. The diagnosis of *Acanthamoeba* sclerokeratitis is often delayed because of the masking effect of the keratitis. Scleritis should be suspected in cases of severe pain, globe tenderness, engorged episcleral vessels, anterior uveitis, and scleral thickening on ultrasonography [3]. It is most commonly anterior and can be either diffuse or nodular. All published case reports with documented extracorneal spread of the *Acanthamoeba* species, including ours, had *nodular* scleritis. Presentation of a *nodular* scleritis should alert the clinician that an infectious origin is more likely, so prudence when starting immunosuppressive treatment is in order.

The pathogenesis of *Acanthamoeba* scleritis is still poorly understood. Both spread of the infection and an autoimmune reaction can be the underlying cause. For a very long time there was only one documented scleral invasion on histological report [6], then in 2009 another case report with *Acanthamoeba* cysts in the limbal region was published [9]. Arnalich-Montiel et al. [10] reported 2 cases of nodular *Acanthamoeba* sclerokeratitis after penetrating and

tectonic keratoplasty. Recently in 2017 and 2018, two more cases of *Acanthamoeba* spread throughout the globe were published [11, 12]. All case reports with documented extracorneal spread of *Acanthamoeba* had had previous intraocular surgery. Our case proves that extracorneal dissemination of *Acanthamoeba* is possible in longstanding disease, even without previous intraocular surgery.

Most published case reports of *Acanthamoeba*-related scleritis showed a purely granulomatous inflammation without cysts on histopathological examination, presuming an immune-mediated mechanism [13–15]. One should consider the possibility that the *Acanthamoeba* cysts were not in the examined histopathological sections, highlighting the importance of serial sections when histopathological examination is not able to show any cysts.

Treatment of *Acanthamoeba* sclerokeratitis is in most cases successful with the association of topical nonsteroidal anti-inflammatory drugs and topical corticosteroids to the anti-amoebic treatment. In some cases, as in ours, it can be very challenging and systemic immunosuppression, even in combination with penetrating keratoplasty, might be necessary to control tissue destruction and pain [4].

We used the stepladder approach described by Iovieno et al. [5]. Topical nonsteroidal anti-inflammatory drugs and steroids are advised as first-line treatment. In case of insufficient response, oral steroids should be added. Unless there is a full response within 1 week, they advise to add steroid-sparing agents such as cyclosporine, azathioprine, or mycophenolate to avoid long-term steroid side effects. In selected cases of severe scleral inflammation, intravenous methylprednisolone or a combination of cyclosporine with mycophenolate or azathioprine can be used. When introducing immunosuppressive treatment, it is recommended to start oral itraconazole or voriconazole. Good results with cyclophosphamide and anti-TNF therapy were described by Igras and Murphy [16], but the side effects of cyclophosphamide, such as severe nausea, vomiting, loss of appetite, hair loss, and even cancer, should be kept in mind.

Our case proves that even when a correct stepladder approach is used, prognosis can be devastating and an enucleation sometimes emerges as the only solution. Clinicians should be aware of the risk of myopathy, fungal infections, and avascular necrosis of the femoral head when high-dose corticosteroids and other immunosuppressive agents are prescribed. When avascular necrosis of the femoral head is suspected, prompt referral to an orthopedic surgeon is necessary, as early diagnosis and treatment yields a better prognosis [7]. In general, patients under immunosuppressive treatment need follow-up by an experienced physician with regular physical and hematological examinations [4].

Conclusion

Scleritis is a devastating complication of *Acanthamoeba* keratitis with a poor prognosis and a high enucleation rate of 6% [5]. The pathogenesis of scleritis is still poorly understood. Multiple case reports with negative histopathological examination assume an immune-mediated cause and suggest immunosuppressive treatment to improve symptoms and to reduce the enucleation rate. In contrast, our case shows that extracorneal spread of *Acanthamoeba* cysts is possible, even without previous intraocular surgery. In case of negative histopathological examination, serial sections should be looked at to exclude an infection. Systemic immunosuppressive treatment, even with prophylactic antiamoebic and antifungal agents, should always be used with the greatest caution. Awareness of the side effects is important

and an experienced physician should monitor these patients with regular physical and hematological examination.

Statement of Ethics

The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The patient gave written informed consent for publication of his case (including publication of images). The study protocol was approved by the Committee on Human Research at the KU Leuven. Information revealing the patient's identity was avoided.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

None.

Author Contributions

S. Bataillie collected the information and wrote the manuscript. R. Van Ginderdeuren diagnosed the extracorneal spread of the *Acanthamoeba* cysts. Furthermore, she provided the pictures and description of the histopathological examination. H. Delbeke, B. Foets, and J. Van Calster were the physicians treating the patient and helped in writing and improving the article.

References

- 1 Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. *Am J Ophthalmol*. 2009 Oct;148(4):487–499.e2.
- 2 Juárez MM, Tártara LI, Cid AG, Real JP, Bermúdez JM, Rajal VB, et al. Acanthamoeba in the eye, can the parasite hide even more? Latest developments on the disease. *Cont Lens Anterior Eye*. 2018 Jun;41(3):245–51.
- 3 Mannis MJ, Tamaru R, Roth AM, Burns M, Thirkill C. Acanthamoeba sclerokeratitis. Determining diagnostic criteria. *Arch Ophthalmol*. 1986 Sep;104(9):1313–7.
- 4 Lee GA, Gray TB, Dart JK, Pavesio CE, Ficker LA, Larkin DF, et al. Acanthamoeba sclerokeratitis: treatment with systemic immunosuppression. *Ophthalmology*. 2002 Jun;109(6):1178–82.
- 5 Iovieno A, Gore DM, Carnt N, Dart JK. Acanthamoeba sclerokeratitis: epidemiology, clinical features, and treatment outcomes. *Ophthalmology*. 2014 Dec;121(12):2340–7.
- 6 Dougherty PJ, Binder PS, Mondino BJ, Glasgow BJ. Acanthamoeba sclerokeratitis. *Am J Ophthalmol*. 1994 Apr;117(4):475–9.
- 7 Cohen-Rosenblum A, Cui Q. Osteonecrosis of the Femoral Head. *Orthop Clin North Am*. 2019 Apr;50(2):139–49.
- 8 Randag AC, Verkerk S, Van Goor AT, Van Rooij J, Wisse RPL, Saelens IEY, et al. Acanthamoeba keratitis in the Netherlands. *Acta Ophthalmol*. 2018;96(Suppl. A260):3.
- 9 Ebrahimi KB, Green WR, Grebe R, Jun AS. Acanthamoeba sclerokeratitis. *Graefes Arch Clin Exp Ophthalmol*. 2009 Feb;47(2):283–6.

- 10 Arnalich-Montiel F, Jaumandreu L, Leal M, Valladares B, Lorenzo-Morales J. Scleral and intraocular amoebic dissemination in *Acanthamoeba* keratitis. *Cornea*. 2013 Dec;32(12):1625–7.
- 11 Mammo Z, Almeida DR, Cunningham MA, Chin EK, Mahajan VB. *Acanthamoeba* endophthalmitis after recurrent keratitis and nodular scleritis. *Retin Cases Brief Rep*. 2017;11(2):180–2.
- 12 Baker MS, Maltry AC, Syed NA, Allen RC. Orbital implant exposure after *Acanthamoeba* panophthalmitis. *Am J Ophthalmol Case Rep*. 2018 Jan;10:48–50.
- 13 Kato K, Hirano K, Nagasaka T, Matsunaga K, Takashima Y, Kondo M. Histopathological examination of *Acanthamoeba* sclerokeratitis. *Clin Ophthalmol*. 2014 Jan;8:251–3.
- 14 Chatterjee S, Agrawal D, Vemuganti GK. Granulomatous inflammation in *Acanthamoeba* sclerokeratitis. *Indian J Ophthalmol*. 2013 Jun;61(6):300–2.
- 15 Shi L, Hager T, Fries FN, Daas L, Holbach L, Hofmann-Rummelt C, et al. Reactive uveitis, retinal vasculitis and scleritis as ocular end-stage of *Acanthamoeba* keratitis: a histological study. *Int J Ophthalmol*. 2019 Dec;12(12):1966–71.
- 16 Igras E, Murphy C. Use of multiple immunosuppressive agents in recalcitrant *Acanthamoeba* scleritis. *BMJ Case Rep*. 2015 Apr;2015:bcr2014208536.

Fig. 1. Anterior scleritis of the left eye with a painful nodule.

Bataillie et al.: How a Devastating Case of *Acanthamoeba* Sclerokeratitis Ended up with Serious Systemic Sequelae

Fig. 2. Localized scleral (yellow arrow) and choroidal swelling in the inferotemporal sector of the left eye.

Fig. 3. Anatomopathological examination of the enucleated left eye (a) showed, after periodic acid-Schiff staining, multiple inflammatory cells (—>) and *Acanthamoeba* cysts (>) in the vitreous (b), sclera (c), and retina (e). d The retina, choroidea, and sclera with magnification of the atrophic retina (e).